Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection

Expert Opinion on Drug Safety

Volumn 16, Issue 5, 2017, Pages 547-559

  Coiras, Mayte ^a   Ambrosioni, Juan ^b   Cervantes, Francisco ^b   Miró, José M ^b   Alcamí, José ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

chronic myeloid leukemia; HIV AIDS; immunomodulation; T cell activation; Tyrosine kinase inhibitors; viral reservoirs

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMMUNOMODULATING AGENT; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; DRUG APPROVAL; DRUG SAFETY; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOMODULATION; IMMUNOREACTIVITY; LYMPHOCYTE ACTIVATION; NONHUMAN; REVIEW; ANTAGONISTS AND INHIBITORS; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; DRUG EFFECTS; ENZYMOLOGY; HIV INFECTIONS; ISOLATION AND PURIFICATION; METABOLISM; VIROLOGY;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 85018741252     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1313224     Document Type: Review

References (115)

1. Zhang Z, Schuler T, Zupancic M, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999;286(5443):1353–1357. PubMed PMID:10558989.
2. Zack JA, Arrigo SJ, Weitsman SR, et al., HIV-1 entry into quiescent primary lymphocytes:molecular analysis reveals a labile, latent viral structure. Cell. 1990;612:213–222.PubMed PMID:2331748.
3. Bermejo M, Martin-Serrano J, Oberlin E, et al. Activation of blood T lymphocytes down-regulates CXCR4 expression and interferes with propagation of X4 HIV strains. Eur J Immunol. 1998; 28(10):3192–3204. 28:10<3192::AID-IMMU3192>3.0.CO;2-E. PubMed PMID:9808188. DOI:10.1002/(SICI)1521-4141(199810)
4. Baldauf HM, Pan X, Erikson E, et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med. 2012;18(11):1682–1687. 2964. PubMed PMID:22972397; PubMed Central PMCID:PMCPMC3828732. DOI:10.1038/nm•• This article highlights for the first time one of the major mechanisms of resistance to infection in resting CD4 lymphocytes, the presence of the restriction factor SAMHD11.
5. Bukrinsky MI, Sharova N, Dempsey MP, et al. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A. 1992;89(14):6580–6584. PubMed PMID:1631159; PubMed Central PMCID:PMCPMC49545.
6. Alcami J, Lain De LT, Folgueira L, et al. Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. Embo J. 1995;14(7):1552–1560.
7. Bosque A, Planelles V., Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood. 2009;113(1):58–65. DOI:10.1182/blood-2008-07-168393
8. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, et al. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7(11):798–812. PubMed PMID:19834480. DOI:10.1038/nrmicro2223•• A classical review covering both the molecular mechanisms of HIV latency and reactivation and the different strategies to tackle the viral reservoirs.
9. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.Science.1997;278(5341):1295–1300.PubMed PMID:9360927.• A classical paper first describing and quantifying the viral reservoir in CD4 lymphocytes from HIV-infected patients.
10. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004; 200(6):749–759. PubMed PMID:15365096; PubMed Central PMCID:PMCPMC2211962. DOI:10.1084/jem.20040874
11. Doitsh G, Cavrois M, Lassen KG, et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell. 2010; 143(5):789–801. PubMed PMID:21111238; PubMed Central PMCID:PMCPMC3026834. DOI:10.1016/j.cell.2010.11.001
12. Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014; 505(7484):509–514. PubMed PMID:24356306; PubMed Central PMCID:PMCPMC4047036. DOI:10.1038/nature12940
13. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004; 200(6):761–770. PubMed PMID:15365095; PubMed Central PMCID:PMCPMC2211967. DOI:10.1084/jem.20041196
14. Monroe KM, Yang Z, Johnson JR, et al. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science. 2014;343(6169):428–432. PubMed PMID:24356113; PubMed Central PMCID:PMCPMC3976200. DOI:10.1126/science.1243640•• In this article, a new mechanisms of cell death linked to the increase of reverse transcripts in the cytosol of infected lymphocytes due to HIV-1 restriction by SAMHD1 is proposed.
15. Cummins NW, Sainski AM, Dai H, et al. Prime, Shock, and Kill:priming CD4 T Cells from HIV Patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size. J Virol. 2016; 90(8):4032–4048. PubMed PMID:26842479; PubMed Central PMCID:PMCPMC4810548. DOI:10.1128/JVI.03179-15
16. Lopez-Huertas MR, Mateos E, Sanchez Del Cojo M, et al. The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+ T lymphocytes:a potential mechanism for persistent viral production. J Biol Chem. 2013; 288(11):7626–7644. PubMed PMID:23364796; PubMed Central PMCID:PMCPMC3597804. DOI:10.1074/jbc.M112.408294
17. Pantaleo G, Demarest JF, Schacker T, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A. 1997;94(1):254–258. PubMed PMID:8990195; PubMed Central PMCID:PMCPMC19306.
18. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278(5342):1447–1450. PubMed PMID:9367954.
19. Plana M, Garcia F, Gallart T, et al., Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology study group of Spanish EARTH-1 Study. Lancet. 1998;3529135:1194–1195.PubMed PMID:9777842.
20. Boritz EA, Darko S, Swaszek L, et al. Multiple origins of virus persistence during natural control of HIV infection. Cell. 2016;166(4):1004–1015. PubMed PMID:27453467; PubMed Central PMCID:PMCPMC4983216. DOI:10.1016/j.cell.2016.06.039• A new actively replicating HIV-1 reservoir–CD4 T-helper follicular cells–that are placed in a CTL-resistant sanctuary is described.
21. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002;417(6884):95–98. PubMed PMID:11986671. DOI:10.1038/417095a• In this article, the paradoxical destruction of CD4-specific lymphocytes targeting the HIV-1 virus due to enhanced susceptibility to infection is described as a qualitative mechanism of immune suppression.
22. Lore K, Smed-Sorensen A, Vasudevan J, et al. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med. 2005;201(12):2023–2033. DOI:10.1084/jem.20042413
23. Lorenzo-Redondo R, Fryer HR, Bedford T, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016; 530(7588):51–56. PubMed PMID:26814962; PubMed Central PMCID:PMCPMC4865637. DOI:10.1038/nature16933
24. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest. 2002;109(5):681–688. PubMed PMID:11877476; PubMed Central PMCID:PMCPMC150896. DOI:10.1172/JCI14522• First paper describing the role of immune suppression to preserve CD4 lymphocyte counts in acutely infected HIV patients. Unfortunately, this article was not confirmed by other authors.
25. Calabrese LH, Lederman MM, Spritzler J, et al. Placebo-controlled trial of cyclosporin-A in HIV-1 disease:implications for solid organ transplantation. J Acquir Immune Defic Syndr. 2002;29(4):356–362. PubMed PMID:11917239.
26. Markowitz M, Vaida F, Hare CB, et al. The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis. 2010; 201(9):1298–1302. PubMed PMID:20235838; PubMed Central PMCID:PMCPMC2851487. DOI:10.1086/651664
27. Andrieu JM, Even P, Venet A, et al. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol. 1988;47(2):181–198. PubMed PMID:3258211.
28. Rizzardi GP, Vaccarezza M, Capiluppi B, et al., Cyclosporin A in combination with HAART in primary HIV-1 infection. J Biol Regul Homeost Agents. 2000;141:79–81.PubMed PMID:10763900.
29. Nicolas D, Ambrosioni J, Sued O, et al. Cyclosporine A in addition to standard ART during primary HIV-1 infection:pilot randomized clinical trial. J Antimicrob Chemother. 2016;dkw462. PubMed PMID:27999018. DOI:10.1093/jac/dkw462
30. Phillips A, Wainberg MA, Coates R, et al. Cyclosporine-induced deterioration in patients with AIDS. Cmaj. 1989;140(12):1456–1460. PubMed PMID:2720530; PubMed Central PMCID:PMCPMC1269983.
31. Chapuis AG, Paolo Rizzardi G, D’Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med. 2000;6:7. Epub 768. PubMed Central PMCID:PMC10888924.
32. Coull JJ, Turner D, Melby T, et al., A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr. 2001;265:423–434.PubMed PMID:11391161.
33. Sankatsing SU, Jurriaans S, Van Swieten P, et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. Aids. 2004;18(14):1925–1931. PubMed PMID:15353978.
34. Garcia F, Plana M, Arnedo M, et al. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection:a randomized pilot study. J Acquir Immune Defic Syndr. 2004;36(3):823–830. PubMed PMID:15213566.
35. Fumero E, Garcia F, Gatell JM., Immunosuppressive drugs as an adjuvant to HIV treatment. J Antimicrob Chemother. 2004;53(3):415–417. PubMed PMID:14963070. DOI:10.1093/jac/dkh123• A review on the potential benefit of immunomodulatory drugs in HIV infection.
36. Garcia F, Plana M, Arnedo M, et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions:a randomized study. Aids. 2003; 17(1):43–51. PubMed PMID:12478068. DOI:10.1097/01.aids.0000042953.95433.79
37. Kong KF, Yokosuka T, Canonigo-Balancio AJ, et al. A motif in the V3 domain of the kinase PKC-theta determines its localization in the immunological synapse and functions in T cells via association with CD28. Nat Immunol. 2011;12(11):1105–1112. DOI:10.1038/ni
38. Gruber T, Pfeifhofer-Obermair C, Baier G. PKCtheta is necessary for efficient activation of NFkappaB, NFAT, and AP-1 during positive selection of thymocytes. Immunol Lett. 2010;132(1–2):6–11. DOI:10.1016/j.imlet.2010.04.008
39. Wang X, Chuang HC, Li JP, et al. Regulation of PKC-theta function by phosphorylation in T cell receptor signaling. Front Immunol. 2012;3:197. PubMed PMID:22798961; PubMed Central PMCID:PMCPMC3393885. DOI:10.3389/fimmu.2012.00197
40. Thomas SM, Brugge JS, Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13:513–609. PubMed PMID:9442882. DOI:10.1146/annurev.cellbio.13.1.513
41. Cooke MP, Perlmutter RM, Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. New Biol. 1989;11:66–74.PubMed PMID:2488273.
42. Olszowy MW, Leuchtmann PL, Veillette A, et al., Comparison of p56lck and p59fyn protein expression in thymocyte subsets, peripheral T cells, NK cells, and lymphoid cell lines. J Immunol. 1995;1559:4236–4240.PubMed PMID:7594580.
43. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene. 2004;23(48):7990–8000. PubMed PMID:15489916. DOI:10.1038/sj.onc.1208074• An interesting revision on the role of tyrosine kinases in lymphocyte activation.
44. Turner JM, Brodsky MH, Irving BA, et al., Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs. Cell. 1990;605:755–765.PubMed PMID:2107025.
45. Ley SC, Marsh M, Bebbington CR, et al., Distinct intracellular localization of Lck and Fyn protein tyrosine kinases in human T lymphocytes. J Cell Biol. 1994;1253:639–649.PubMed PMID:7513706; PubMed Central PMCID:PMCPMC2119993.
46. Lin K, Longo NS, Wang X, et al., Lck domains differentially contribute to pre-T cell receptor (TCR)- and TCR-alpha/beta-regulated developmental transitions. J Exp Med. 2000;1914:703–716.PubMed PMID:10684862; PubMed Central PMCID:PMCPMC2195836.
47. Coiras M, Bermejo M, Descours B, et al. IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, improving early steps of HIV-1 life cycle. Cell Rep. 2016;14(9):2100–2107. PubMed PMID:26923586; PubMed Central PMCID:PMCPMC5063304. DOI:10.1016/j.celrep.2016.02.022•• First description of the ability of dasatinib to interfere with SAMHD1.
48. Simeoni L, Smida M, Posevitz V, et al. Right time, right place:the organization of membrane proximal signaling. Semin Immunol. 2005;17(1):35–49. DOI:10.1016/j.smim.2004.09.002
49. Ghosh S, May MJ, Kopp EB, NF-kappa B and Rel proteins:evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–260. PubMed PMID:9597130. DOI:10.1146/annurev.immunol.16.1.225
50. Hiscott J, Kwon H, Genin P. Hostile takeovers:viral appropriation of the NF-kappaB pathway. J Clin Invest. 2001;107(2):143–151. DOI:10.1172/JCI11918
51. Kwon H, Pelletier N, DeLuca C, et al. Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells. J Biol Chem. 1998;273(13):7431–7440. PubMed PMID:9516441.
52. Quinto I, Mallardo M, Baldassarre F, et al., Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) and the implications for vaccine development. J Biol Chem. 1999;27425:17567–17572.PubMed PMID:10364191.
53. Bermejo M, Lopez-Huertas MR, Hedgpeth J, et al. Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription. Biochem Pharmacol. 2015; 94(4):241–256. PubMed PMID:25732195. DOI:10.1016/j.bcp.2015.02.009
54. Bermejo M, Lopez-Huertas MR, Garcia-Perez J, et al. Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. Biochem Pharmacol. 2016;106:30–45. PubMed PMID:26851491. DOI:10.1016/j.bcp.2016.02.002• First description of the role of tyrosine kinase inhibitors in SAMHD1 regulation.
55. D’Antonio J. Chronic myelogenous leukemia. Clin J Oncol Nurs. 2005;9(5):535–538. DOI:10.1188/05.CJON.535-538
56. Sabir N, Iqbal Z, Aleem A, et al. Prognostically significant fusion oncogenes in Pakistani patients with adult acute lymphoblastic leukemia and their association with disease biology and outcome. Asian Pac J Cancer Prev. 2012;13(7):3349–3355. PubMed PMID:22994759.
57. Andreieva SV, Korets KV, Kyselova OA, et al., Chronic myeloid leukemia in patient with the Klinefelter syndrome. Exp Oncol. 2016;383:195–197.PubMed PMID:27685529.
58. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330–1340. DOI:10.1056/NEJM199904293401706
59. Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond–exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol. 2009;6(9):535–543. DOI:10.1038/nrclinonc.2009.112
60. Woessner DW, Lim CS, Deininger MW. Development of an effective therapy for chronic myelogenous leukemia. Cancer J. 2011;17(6):477–486. DOI:10.1097/PPO.0b013e318237e5b7
61. Steegmann JL, Cervantes F, Le Coutre P, et al. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012;53(12):2351–2361. DOI:10.3109/10428194.2012.695779
62. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc. 2015;90(10):1440–1454. PubMed PMID:26434969. DOI:10.1016/j.mayocp.2015.08.010• An interesting revision on the treatment of chronic myeloid leukemia, describing the different tyrosine kinase inhibitors.
63. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016; 30(8):1648–1671. PubMed PMID:27121688; PubMed Central PMCID:PMCPMC4991363. DOI:10.1038/leu.2016.104
64. O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005; 65(11):4500–4505. PubMed PMID:15930265. DOI:10.1158/0008-5472.CAN-05-0259
65. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006; 66(23):11314–11322. PubMed PMID:17114238. DOI:10.1158/0008-5472.CAN-06-1199
66. Simoneau CA. Treating chronic myeloid leukemia:improving management through understanding of the patient experience. Clin J Oncol Nurs. 2013;17(1):E13–20. DOI:10.1188/13.CJON.E13-E20
67. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210–4218. DOI:10.1200/JCO.2015.62
68. Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med. 2010;16(4):351–356. DOI:10.1097/MCP.0b013e328338c486
69. (EMA) EMA. Sprycel® product information. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000709/WC500056993.pdf
70. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011; 118(17):4567–4576. PubMed PMID:21865346; PubMed Central PMCID:PMCPMC4916618. DOI:10.1182/blood-2011-05-355594
71. Miller GD, Bruno BJ, Lim CS, Resistant mutations in CML and Ph(+)ALL - role of ponatinib. Biologics. 2014;8:243–254. PubMed PMID:25349473; PubMed Central PMCID:PMCPMC4208348. DOI:10.2147/BTT.S50734
72. Caldemeyer L, Dugan M, Edwards J, Akard L. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2016 Apr;11(2):71–79.
73. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2016. PubMed PMID:27749369. DOI:10.1097/COH.0000000000000327
74. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85(5):387–398. DOI:10.1111/j.1600-0609.2010.01501.x
75. Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004; 18(8):1332–1339. PubMed PMID:15190258. DOI:10.1038/sj.leu.2403401
76. Chen J, Schmitt A, Chen B, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12:(5B):2107-18. PubMed PMID:18194453; PubMed Central PMCID:PMCPMC4506175. DOI:10.1111/j.1582-4934.2008.00234.x
77. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008; 111(3):1366–1377. PubMed PMID:17962511; PubMed Central PMCID:PMCPMC2214733. DOI:10.1182/blood-2007-04-084814
78. Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116(5):772–782. PubMed PMID:20413659. DOI:10.1182/blood-2009-12-256800• A description of immunological changes induced by tyrosine kinase inhibitors related with toxic effects.
79. Mustjoki S, Auvinen K, Kreutzman A, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 2013; 27(4):914–924. PubMed PMID:23192016. DOI:10.1038/leu.2012.348
80. Schiffer CA, Cortes JE, Hochhaus A, et al. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia:effects on response and toxicity. Cancer. 2016;122(9):1398–1407. PubMed PMID:26998677. DOI:10.1002/cncr.29933• A description of the potential role of recovered lymphocytes in the response and control of chronic myeloid leukemia.
81. Rodriguez GH, Ahmed SI, Al-Akhrass F, et al. Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications. Leuk Lymphoma. 2012;53(8):1530–1535. DOI:10.3109/10428194.2012.656626
82. Benhar M, Shytaj IL, Stamler JS, et al. Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J Clin Invest. 2016;126(5):1630–1639. DOI:10.1172/JCI85339
83. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response:indispensable for therapeutic success? J Clin Invest. 2008;118(6):1991–2001. DOI:10.1172/JCI35180
84. Lopez-Huertas MR, Mateos E, Diaz-Gil G, et al. Protein kinase Ctheta is a specific target for inhibition of the HIV type 1 replication in CD4+ T lymphocytes. J Biol Chem. 2011; 286(31):27363–27377. PubMed PMID:21669868; PubMed Central PMCID:PMCPMC3149330. DOI:10.1074/jbc.M110.210443
85. Lahouassa H, Daddacha W, Hofmann H, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012; 13(3):223–228. 2236. PubMed PMID:22327569; PubMed Central PMCID:PMCPMC3771401. DOI:10.1038/ni
86. Cribier A, Descours B, Valadao AL, et al. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Rep. 2013;3(4):1036–1043. DOI:10.1016/j.celrep.2013.03.017
87. Giansanti P, Preisinger C, Huber KV, et al. Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics. ACS Chem Biol. 2014; 9(7):1490–1498. PubMed PMID:24804581. DOI:10.1021/cb500116c
88. Bullen CK, Laird GM, Durand CM, et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014;20(4):425–429. DOI:10.1038/nm
89. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med PubMed PMID:21090961; PubMed Central PMCID:PMCPMC3759035. 2011;62:141–155. DOI:10.1146/annurev-med-042909-093756•• A review on the pathogenic mechanisms leading to immunological damage due to chronic activation and exhaustion of the immune system by persistent HIV replication.
90. Aberg JA, Aging, inflammation, and HIV infection. Top Antivir Med. 2012;203:101–105.PubMed PMID:22954610.
91. Saussele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30(8):1638–1647. PubMed PMID:27133824; PubMed Central PMCID:PMCPMC4980559. DOI:10.1038/leu.2016.115• A concept paper discussing the successful interruption of treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia that show deep molecular response.
92. Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial):a multicentre phase 2 trial. Lancet Haematol. 2015; 2(12):e528–35. PubMed PMID:26686407. DOI:10.1016/S2352-3026(15)00196-9
93. Mizoguchi I, Yoshimoto T, Katagiri S, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci. 2013; 104(9):1146–1153. PubMed PMID:23758044. DOI:10.1111/cas.12216
94. Zitvogel L, Rusakiewicz S, Routy B, et al. Immunological off-target effects of imatinib. Nat Rev Clin Oncol. 2016;13(7):431–446. DOI:10.1038/nrclinonc.2016.41
95. Cao W, Vyboh K, Routy B, et al. Imatinib for highly chemoresistant Kaposi sarcoma in a patient with long-term HIV control:a case report and literature review. Curr Oncol. 2015;22(5):e395–9. DOI:10.3747/co.22
96. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. Plos One. 2012; 7(3):e33948. PubMed PMID:22479485; PubMed Central PMCID:PMCPMC3316511. DOI:10.1371/journal.pone.0033948
97. Buzon MJ, Martin-Gayo E, Pereyra F, et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol. 2014;88(17):10056–10065. PubMed PMID:24965451; PubMed Central PMCID:PMCPMC4136362. DOI:10.1128/JVI.01046-14• This article describes the impact of early treatment on the establishment and size of the HIV reservoir.
98. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors:implications for diagnosis and staging of primary HIV infection. Aids. 2003;17(13):1871–1879. PubMed PMID:12960819. DOI:10.1097/01.aids.0000076308.76477.b8•• Classical article describing the criteria to define the different stages in acute HIV-1 infection.
99. Ndhlovu ZM, Kamya P, Mewalal N, et al. Magnitude and kinetics of CD8+ T cell activation during hyperacute HIV infection impact viral set point. Immunity. 2015; 43(3):591–604. PubMed PMID:26362266; PubMed Central PMCID:PMCPMC4575777. DOI:10.1016/j.immuni.2015.08.012
100. Kloverpris HN, Kazer SW, Mjosberg J, et al. Innate lymphoid cells are depleted irreversibly during acute HIV-1 infection in the absence of viral suppression. Immunity. 2016; 44(2):391–405. PubMed PMID:26850658. DOI:10.1016/j.immuni.2016.01.006
101. Deng K, Pertea M, Rongvaux A, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015; 517(7534):381–385. PubMed PMID:25561180; PubMed Central PMCID:PMCPMC4406054. DOI:10.1038/nature14053
102. Shytaj IL, Nickel G, Arts E, et al. Two-year follow-up of macaques developing intermittent control of the human immunodeficiency virus homolog simian immunodeficiency virus SIVmac251 in the chronic phase of infection. J Virol. 2015; 89(15):7521–7535. PubMed PMID:25972547; PubMed Central PMCID:PMCPMC4505651. DOI:10.1128/JVI.00396-15
103. Harmon B, Campbell N, Ratner L. Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step. Plos Pathog. 2010;6(6):e1000956. DOI:10.1371/journal.ppat.1000956
104. Pogliaghi M, Papagno L, Lambert S, et al. The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients. Aids. 2014; 28(2):278–281. PubMed PMID:24361684. DOI:10.1097/QAD.0000000000000073
105. Dhurve SA, Dhurve AS. Bone marrow abnormalities in HIV disease. Mediterr J Hematol Infect Dis. 2013;5(1):e2013033. DOI:10.4084/MJHID.2013.033
106. Ambrosioni J, Nicolas D, Sued O, et al. Update on antiretroviral treatment during primary HIV infection. Expert Rev Anti Infect Ther. 2014;12(7):793–807. DOI:10.1586/14787210.2014.913981
107. Ando T, Kojima K, Isoda H, et al. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015; 102(3):379–382. PubMed PMID:25842192. DOI:10.1007/s12185-015-1788-y
108. Soriano V, Labarga P, De Mendoza C, et al. Emerging challenges in managing hepatitis B in HIV patients. Curr HIV/AIDS Rep. 2015; 12(3):344–352. PubMed PMID:26156570. DOI:10.1007/s11904-015-0275-7
109. Nguyen T, McNicholl I, Custodio JM, et al., Drug interactions with cobicistat- or ritonavir-boosted elvitegravir. AIDS Rev. 2016;182:101–111.PubMed PMID:27196356.
110. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer. 2010; 116(6):1582–1591. PubMed PMID:20108303. DOI:10.1002/cncr.24927
111. Abbas R, Hsyu PH. Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clin Pharmacokinet. 2016;55(10):1191–1204. DOI:10.1007/s40262-016-0391-6
112. (EMA) EMA. Iclusig® Prescribing Information. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002695/WC500145649.pdf
113. EACS 2017. Available from:http://www.eacsociety.org/files/guidelines_8.2-english.pdf
114. Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults:2016 recommendations of the international antiviral society-USA panel. Jama. 2016; 316(2):191–210. 8900. PubMed PMID:27404187; PubMed Central PMCID:PMCPMC5012643. DOI:10.1001/jama.2016
115. Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009; 458(7235):206–210. PubMed PMID:19078956; PubMed Central PMCID:PMCPMC2753387. DOI:10.1038/nature07662